title: [Regression of vena cava tumour thrombus in response to sorafenib].
abstract: Ten percent of patients with kidney cancer have associated vena cava thrombus, which is associated with a high operative morbidity. Up to now, no medical treatment has allowed regression of vena cava tumour thrombus. The authors report the case of a 62-year-old patient with left kidney cancer associated with vena cava tumour thrombus. After surgical resection, the patient relapsed in the form of vena cava thrombus associated with right renal vein thrombus, responsible for renal insufficiency requiring dialysis. Sorafenib therapy allowed regression of the vena cava thrombus, suspension of haemodialysis and local disease control with a follow-up of one year. This case report justifies a review of the place of anti-angiogenic therapy in the treatment of kidney cancer.
authors.affiliation: Service d'Urologie et Transplantation Rénale, Groupe Hospitalier de la Pitié-Salpêtrière, Université Pierre-et-Marie-Curie, Paris, France. frederic.thibault@psl.aphp.fr <frederic.thibault@psl.aphp.fr>
authors.forename: F
authors.initials: F
authors.lastname: Thibault
authors.forename: H
authors.initials: H
authors.lastname: Izzedine
authors.forename: V
authors.initials: V
authors.lastname: Sultan
authors.forename: S
authors.initials: S
authors.lastname: Bart
authors.forename: B
authors.initials: B
authors.lastname: Billemont
authors.forename: O
authors.initials: O
authors.lastname: Rixe
authors.forename: M-O
authors.initials: MO
authors.lastname: Bitker
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000150:complications* / Q000473:pathology / Q000601:surgery; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000150:complications* / Q000473:pathology / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor; D012082:Renal Veins; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome; D014684:Venae Cavae; D020246:Venous Thrombosis / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor